The Three P's: Parotid, PD-L1, and Pembrolizumab

We present a case of recurrent, platinum-refractory undifferentiated carcinoma of the parotid which was treated with checkpoint inhibitor, Pembrolizumab, and achieved a complete response to therapy. We review the literature of checkpoint inhibitor use in undifferentiated carcinoma of the parotid.

Detalles Bibliográficos
Autores principales: Wiggins, Amanda, Arter, Zhaohui, Kerns, Tamie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594310/
https://www.ncbi.nlm.nih.gov/pubmed/31308983
http://dx.doi.org/10.1155/2019/2305315
Descripción
Sumario:We present a case of recurrent, platinum-refractory undifferentiated carcinoma of the parotid which was treated with checkpoint inhibitor, Pembrolizumab, and achieved a complete response to therapy. We review the literature of checkpoint inhibitor use in undifferentiated carcinoma of the parotid.

Ejemplares similares